Developer docs
API playgroundTry for free, no card

Search company profiles

Digma Medical

Full company profile

uuid0009ma6

Namestring
Digma Medical
Legal namestring
Digma Medical, Ltd.
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Digma Medical Ltd. is a clinical-stage medical device company developing the Endoscopic Gastrointestinal Ablation Device (EGAD), a minimally invasive laser-based balloon-catheter system intended for the treatment of Barrett's Esophagus—a pre-cancerous condition that can progress to esophageal adenocarcinoma. The EGAD platform delivers contactless, depth-controlled laser ablation through a single-use catheter passed via the working channel of standard GI endoscopes, using a proprietary dual-wavelength guidance system (a visible red pointer for targeting and an NIR therapeutic laser for ablation) with a balloon-centered design that stabilizes delivery. The procedure is designed for the standard GI endoscopy suite without requiring additional imaging equipment or fluoroscopy.

The company's commercial model targets hospital gastroenterology departments and outpatient endoscopy centers and is structured as a capital-plus-consumables offering: an EGAD treatment console paired with single-use catheters whose recurring per-procedure use generates a razor-and-blade revenue stream. The Digma System is investigational-only and not approved for sale in any geography; pricing is not publicly disclosed and go-to-market relies on direct enterprise sales, scientific advisory engagement (led by Prof. Ohad Etzion, Director of GI at Soroka), and medical conference presence. The company is privately held, headquartered at Ha'arava St 1, Giv'at Shmuel, Israel, with an 11–50 employee footprint, and is backed by Accelmed, Arkin Holdings, Peregrine Ventures, MedTech Innovator, and Israel's Office of the Chief Scientist across rounds dated 2013, 2015, 2016, 2022, and 2023 (amounts undisclosed).

Leadership combines deep medical-device operating experience with venture capital reach. Co-founder and CTO Ilan Ben-Oren is the author of more than 60 patents and previously founded or served as CTO at Eximo Medical (acquired by AngioDynamics), Exalenz Bioscience (acquired by Meridian BioScience), and Oridion Medical (acquired by Covidien). Co-founder Dr. Irit Yaniv is Founding Partner and CEO of Almeda Ventures and Managing Partner at Accelmed Ventures II. General Manager Shlomit Chappel-Ram, PhD, MBA, previously held senior roles at Nano Dimension, Edwards Lifesciences, and Medinol. Board Chairman Chris Rowland is a 35+ year MedTech executive with prior companies acquired by Covidien/Medtronic, Teleflex, and a Chinese strategic.

Short descriptiontext

Digma Medical Ltd. is a clinical-stage Israeli medical device company developing the EGAD, a laser-based balloon-catheter system for minimally invasive ablation of Barrett's Esophagus, targeting hospital gastroenterology departments and outpatient endoscopy centers through an investigational-use-only program.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGivat Shmuel, Israel
HQ citystring
Givat Shmuel
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
endoscopic ablation devices, gastrointestinal medical devices, Barrett's Esophagus treatment, laser balloon catheter, GI oncology therapeutics
Industry1 code
PRIMARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Endoscopic Gastrointestinal Ablation Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1EGAD Console
TypeHardware Sales
Description

Capital equipment sale of EGAD treatment console to hospitals and GI endoscopy centers

digmamedical.com
2Single-use Catheters
TypeHardware Sales
Description

Recurring consumable revenue from single-use catheters compatible with the console, providing recurring revenue stream tied to procedure volume

digmamedical.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Digma Medical develops and intends to commercialize the Endoscopic Gastrointestinal Ablation Device (EGAD), a minimally invasive, laser-based balloon-catheter system for treating Barrett's Esophagus. The system comprises an EGAD Console (capital equipment) and a single-use balloon catheter delivered through the working channel of standard GI endoscopes, enabling contactless, uniform, depth-controlled tissue ablation that protects deeper layers such as the muscularis. The product is currently investigational and not yet available for sale.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Increases risk of esophageal adenocarcinoma by up to 125x without treatment
+2 more records
Product overview1 text field

Digma Medical offers a unified medical device system called the Endoscopic Gastrointestinal Ablation Device (EGAD), consisting of two integrated components: an EGAD Console and an EGAD Single-use Catheter. The system provides contactless, uniform, depth-controlled laser ablation for Barrett's Esophagus treatment, designed for use in standard GI endoscopy suites without requiring additional imaging equipment.

Product and service3 records
1Endoscopic Gastrointestinal Ablation Device (EGAD) System
CategoryEndoscopic Gastrointestinal Ablation Device
Description

A minimally invasive, laser-based balloon-catheter system for treating Barrett's Esophagus, comprising a console and a single-use catheter that delivers contactless, uniform, depth-controlled ablation guided by imaging and is compatible with standard GI endoscopes. Targeted at hospital gastroenterology departments and outpatient endoscopy centers.

2EGAD Console
CategoryCapital equipment / Console
Description

Capital equipment component of the EGAD system that delivers laser energy via the single-use catheter. Designed for use in standard GI endoscopy suites without requiring additional imaging equipment or fluoroscopy.

3EGAD Single-use Catheter
CategorySingle-use consumable catheter
Description

Single-use balloon-catheter delivered through the working channel of standard GI endoscopes, featuring balloon-centered laser delivery for stable, contactless, depth-controlled ablation with selective tissue interaction. Designed as a recurring consumable tied to procedure volume.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Owner of the Barrx radiofrequency ablation system, the dominant endoscopic BE ablation platform. Directly competes with Digma's EGAD in the same GI procedure setting and represents the primary incumbent Digma must displace for share.

TypeDirect peer
Description

Developer of the truFreeze spray cryotherapy system for esophageal disease including Barrett's Esophagus. Competes head-to-head with EGAD in the BE ablation indication via a different energy modality (cryo vs. laser).

TypeEmerging player
Description

UK-based developer of advanced energy endoscopic devices (Speedboat, CROMA) used in GI therapeutic procedures. Comparable as a developer of energy-based endoscopic therapeutic platforms targeting GI disease, though with a different mechanism and broader procedural scope.

TypeBroad incumbent
Description

German manufacturer of electrosurgical and therapeutic endoscopy platforms widely used in GI ablation and resection procedures. Comparable as a broad incumbent energy-based endoscopy equipment vendor that GI departments already procure from.

TypeBroad incumbent
Description

Global leader in GI endoscopy systems and accessories, including the scope platforms through which EGAD is delivered. Comparable as the dominant incumbent in GI endoscopy suites where Digma's product is designed to be used.

TypeBroad incumbent
Description

Endoscopy systems and accessories provider (HOYA Group) including GI scopes. Comparable as the second major GI endoscope platform vendor whose installed base defines the working-channel interface EGAD is designed to fit.

TypeBroad incumbent
Description

Diversified interventional GI player with endoscopic resection, hemostasis, and tissue management products. Comparable as a broad incumbent in interventional GI with the strategic optionality to acquire or partner with emerging BE ablation assets like Digma.

TypeOthers
Description

Acquired Digma co-founder Ilan Ben-Oren's prior company Eximo Medical, giving it direct familiarity with laser-based catheter ablation technology. Comparable as a strategic acquirer precedent for Digma's technology platform and a likely bidder at exit.

9Steris
TypeBroad incumbent
Description

Post-Cantel integration, Steris distributes GI endoscopy infection-prevention and procedural consumables used in BE workflows. Comparable as an incumbent channel and consumables partner already present in BE-treating endoscopy suites.

TypeEmerging player
Description

Clinical-stage company developing endoscopic GI interventions targeting metabolic disease (Type-2 Diabetes / NASH). Comparable to the short-description positioning Digma has publicly used around glycemic/NASH, and as an adjacent emerging endoscopic GI platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Digma Medical

Endoscopic Gastrointestinal Ablation Devicesdigmamedical.com

Digma Medical Ltd. is a clinical-stage Israeli medical device company developing the EGAD, a laser-based balloon-catheter system for minimally invasive ablation of Barrett's Esophagus, targeting hospital gastroenterology departments and outpatient endoscopy centers through an investigational-use-only program.

What Digma Medical does

Digma Medical Ltd. is a clinical-stage medical device company developing the Endoscopic Gastrointestinal Ablation Device (EGAD), a minimally invasive laser-based balloon-catheter system intended for the treatment of Barrett's Esophagus—a pre-cancerous condition that can progress to esophageal adenocarcinoma. The EGAD platform delivers contactless, depth-controlled laser ablation through a single-use catheter passed via the working channel of standard GI endoscopes, using a proprietary dual-wavelength guidance system (a visible red pointer for targeting and an NIR therapeutic laser for ablation) with a balloon-centered design that stabilizes delivery. The procedure is designed for the standard GI endoscopy suite without requiring additional imaging equipment or fluoroscopy.

The company's commercial model targets hospital gastroenterology departments and outpatient endoscopy centers and is structured as a capital-plus-consumables offering: an EGAD treatment console paired with single-use catheters whose recurring per-procedure use generates a razor-and-blade revenue stream. The Digma System is investigational-only and not approved for sale in any geography; pricing is not publicly disclosed and go-to-market relies on direct enterprise sales, scientific advisory engagement (led by Prof. Ohad Etzion, Director of GI at Soroka), and medical conference presence. The company is privately held, headquartered at Ha'arava St 1, Giv'at Shmuel, Israel, with an 11–50 employee footprint, and is backed by Accelmed, Arkin Holdings, Peregrine Ventures, MedTech Innovator, and Israel's Office of the Chief Scientist across rounds dated 2013, 2015, 2016, 2022, and 2023 (amounts undisclosed).

Leadership combines deep medical-device operating experience with venture capital reach. Co-founder and CTO Ilan Ben-Oren is the author of more than 60 patents and previously founded or served as CTO at Eximo Medical (acquired by AngioDynamics), Exalenz Bioscience (acquired by Meridian BioScience), and Oridion Medical (acquired by Covidien). Co-founder Dr. Irit Yaniv is Founding Partner and CEO of Almeda Ventures and Managing Partner at Accelmed Ventures II. General Manager Shlomit Chappel-Ram, PhD, MBA, previously held senior roles at Nano Dimension, Edwards Lifesciences, and Medinol. Board Chairman Chris Rowland is a 35+ year MedTech executive with prior companies acquired by Covidien/Medtronic, Teleflex, and a Chinese strategic.

Digma Medical firmographics

Firmographics
Name
Digma Medical
Legal name
Digma Medical, Ltd.
Website
https://digmamedical.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Digma Medical Ltd. is a clinical-stage Israeli medical device company developing the EGAD, a laser-based balloon-catheter system for minimally invasive ablation of Barrett's Esophagus, targeting hospital gastroenterology departments and outpatient endoscopy centers through an investigational-use-only program.
Ownership category
akta.pro rank

Digma Medical industry classification

Industry
Product category
Endoscopic Gastrointestinal Ablation Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Endoscopic ablation devices
  • Gastrointestinal medical devices
  • Barrett's Esophagus treatment
  • Laser balloon catheter
  • GI oncology therapeutics

Where Digma Medical is headquartered

Location

Headquarters

HQ city
Givat Shmuel
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Digma Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. EGAD Console: Capital equipment sale of EGAD treatment console to hospitals and GI endoscopy centers
  2. Single-use Catheters: Recurring consumable revenue from single-use catheters compatible with the console, providing recurring revenue stream tied to procedure volume

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Digma Medical product offering

Product offering

Core offering

Digma Medical develops and intends to commercialize the Endoscopic Gastrointestinal Ablation Device (EGAD), a minimally invasive, laser-based balloon-catheter system for treating Barrett's Esophagus. The system comprises an EGAD Console (capital equipment) and a single-use balloon catheter delivered through the working channel of standard GI endoscopes, enabling contactless, uniform, depth-controlled tissue ablation that protects deeper layers such as the muscularis. The product is currently investigational and not yet available for sale.

Product overview

Digma Medical offers a unified medical device system called the Endoscopic Gastrointestinal Ablation Device (EGAD), consisting of two integrated components: an EGAD Console and an EGAD Single-use Catheter. The system provides contactless, uniform, depth-controlled laser ablation for Barrett's Esophagus treatment, designed for use in standard GI endoscopy suites without requiring additional imaging equipment.

Differentiator

Problem solved

Functional benefit

Products and services

  • Endoscopic Gastrointestinal Ablation Device (EGAD) System A minimally invasive, laser-based balloon-catheter system for treating Barrett's Esophagus, comprising a console and a single-use catheter that delivers contactless, uniform, depth-controlled ablation guided by imaging and is compatible with standard GI endoscopes. Targeted at hospital gastroenterology departments and outpatient endoscopy centers.
  • EGAD Console Capital equipment component of the EGAD system that delivers laser energy via the single-use catheter. Designed for use in standard GI endoscopy suites without requiring additional imaging equipment or fluoroscopy.
  • EGAD Single-use Catheter Single-use balloon-catheter delivered through the working channel of standard GI endoscopes, featuring balloon-centered laser delivery for stable, contactless, depth-controlled ablation with selective tissue interaction. Designed as a recurring consumable tied to procedure volume.

Quantifiable outcome

  • Increases risk of esophageal adenocarcinoma by up to 125x without treatment
  • +2 more outcomes

Companies that use Digma Medical

Customer profile

Segments2 records

Ideal customer profiles1 record

Digma Medical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Digma Medical partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Digma Medical competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Owner of the Barrx radiofrequency ablation system, the dominant endoscopic BE ablation platform. Directly competes with Digma's EGAD in the same GI procedure setting and represents the primary incumbent Digma must displace for share.
  • ERBE Elektromedizin: German manufacturer of electrosurgical and therapeutic endoscopy platforms widely used in GI ablation and resection procedures. Comparable as a broad incumbent energy-based endoscopy equipment vendor that GI departments already procure from.
  • Olympus Corporation: Global leader in GI endoscopy systems and accessories, including the scope platforms through which EGAD is delivered. Comparable as the dominant incumbent in GI endoscopy suites where Digma's product is designed to be used.
  • Pentax Medical: Endoscopy systems and accessories provider (HOYA Group) including GI scopes. Comparable as the second major GI endoscope platform vendor whose installed base defines the working-channel interface EGAD is designed to fit.
  • Boston Scientific: Diversified interventional GI player with endoscopic resection, hemostasis, and tissue management products. Comparable as a broad incumbent in interventional GI with the strategic optionality to acquire or partner with emerging BE ablation assets like Digma.
  • Steris: Post-Cantel integration, Steris distributes GI endoscopy infection-prevention and procedural consumables used in BE workflows. Comparable as an incumbent channel and consumables partner already present in BE-treating endoscopy suites.

Direct peers

  • CSA Medical: Developer of the truFreeze spray cryotherapy system for esophageal disease including Barrett's Esophagus. Competes head-to-head with EGAD in the BE ablation indication via a different energy modality (cryo vs. laser).

Emerging players

  • Creo Medical: UK-based developer of advanced energy endoscopic devices (Speedboat, CROMA) used in GI therapeutic procedures. Comparable as a developer of energy-based endoscopic therapeutic platforms targeting GI disease, though with a different mechanism and broader procedural scope.
  • Fractyl Health: Clinical-stage company developing endoscopic GI interventions targeting metabolic disease (Type-2 Diabetes / NASH). Comparable to the short-description positioning Digma has publicly used around glycemic/NASH, and as an adjacent emerging endoscopic GI platform.

Others

  • AngioDynamics: Acquired Digma co-founder Ilan Ben-Oren's prior company Eximo Medical, giving it direct familiarity with laser-based catheter ablation technology. Comparable as a strategic acquirer precedent for Digma's technology platform and a likely bidder at exit.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key highlights6 records

Customer concentration

Digma Medical social profiles

Digital presence

Digma Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Digma Medical leadership team

Management profile

Number of profiles

Profiles6 records

Digma Medical funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Digma Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Digma Medical

What does Digma Medical do?

Digma Medical develops and intends to commercialize the Endoscopic Gastrointestinal Ablation Device (EGAD), a minimally invasive, laser-based balloon-catheter system for treating Barrett's Esophagus. The system comprises an EGAD Console (capital equipment) and a single-use balloon catheter delivered through the working channel of standard GI endoscopes, enabling contactless, uniform, depth-controlled tissue ablation that protects deeper layers such as the muscularis. The product is currently investigational and not yet available for sale.

Is Digma Medical a public or private company?

Digma Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Digma Medical founded?

Digma Medical was founded in 2013. It employs 11 to 50 people.

Where is Digma Medical based?

Digma Medical is headquartered in Givat Shmuel, Israel, in the Middle East region.

How does Digma Medical make money?

Two revenue lines are on record. EGAD Console is the primary driver. The others are single-use Catheters.

Who are Digma Medical's main competitors?

Broad incumbents on record are Medtronic, ERBE Elektromedizin, Olympus Corporation, Pentax Medical, Boston Scientific and Steris. CSA Medical is listed as a direct peer. Emerging players are Creo Medical and Fractyl Health. AngioDynamics is listed as an others.

Does Digma Medical have an API?

No public API is recorded for Digma Medical.

What industry is Digma Medical in?

Digma Medical's product category is Endoscopic Gastrointestinal Ablation Devices. Its primary akta.pro industry code is HLAHADAC, Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals